102 related articles for article (PubMed ID: 32646620)
1. 21-gene recurrence score testing utilization among older women from different races: A population-based study.
Gulbahce HE; White S; Herget KA; Stoddard G; Camp NJ; Buys SS; Sweeney C
J Geriatr Oncol; 2021 Mar; 12(2):206-211. PubMed ID: 32646620
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy and 21-gene recurrence score testing for older breast cancer patients: A competing-risks analysis.
Zhou P; Zhang WW; Bao Y; Wang J; Lian CL; He ZY; Wu SG
Breast; 2020 Dec; 54():319-327. PubMed ID: 33278648
[TBL] [Abstract][Full Text] [Related]
3. 21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer.
Kizy S; Altman AM; Marmor S; Denbo JW; Jensen EH; Tuttle TM; Hui JYC
J Geriatr Oncol; 2019 Mar; 10(2):322-329. PubMed ID: 30093354
[TBL] [Abstract][Full Text] [Related]
4. Genomic expression assay testing among American Indian and Alaska Native women with breast cancer.
Marmor S; Longacre CF; Altman AM; Hui JYC; Jensen EH; Tuttle TM
Cancer; 2020 Dec; 126(24):5222-5229. PubMed ID: 32926435
[TBL] [Abstract][Full Text] [Related]
5. Racial differences in predictive value of the 21-gene recurrence score assay: a population-based study using the SEER database.
Jung J; Hwang KT; Choi IS; Kim BH; Oh S; Kim J; Park JH; Park JH; Paek SH; Jeon SY; Yeo TH
Breast Cancer; 2022 Sep; 29(5):889-898. PubMed ID: 35616777
[TBL] [Abstract][Full Text] [Related]
6. Distribution of 21-Gene Recurrence Scores in Male Breast Cancer in the United States.
Altman AM; Kizy S; Yuan J; Denbo JW; Jensen EH; Hui JYC; Tuttle TM; Marmor S
Ann Surg Oncol; 2018 Aug; 25(8):2296-2302. PubMed ID: 29907942
[TBL] [Abstract][Full Text] [Related]
7. Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.
Orucevic A; Heidel RE; Bell JL
Breast Cancer Res Treat; 2016 Jun; 157(3):427-35. PubMed ID: 27206678
[TBL] [Abstract][Full Text] [Related]
8. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast.
Kizy S; Huang JL; Marmor S; Tuttle TM; Hui JYC
Breast Cancer Res Treat; 2017 Oct; 165(3):757-763. PubMed ID: 28647915
[TBL] [Abstract][Full Text] [Related]
9. 21-Gene Recurrence Score Testing in HER2-positive Patients.
Altman AM; Marmor S; Tuttle TM; Hui JYC
Clin Breast Cancer; 2019 Apr; 19(2):126-130. PubMed ID: 30595493
[TBL] [Abstract][Full Text] [Related]
10. Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer.
Yang DD; Buscariollo DL; Cronin AM; Weng S; Hughes ME; Bleicher RJ; Cohen AL; Javid SH; Edge SB; Moy B; Niland JC; Wolff AC; Hassett MJ; Punglia RS
Radiat Oncol; 2020 Aug; 15(1):198. PubMed ID: 32799886
[TBL] [Abstract][Full Text] [Related]
11. Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer.
Mutonga M; Speedy S; Rademaker A; Liu D; Uthe R; Jain S; Gradishar WJ; Flaum L; Santa-Maria CA
Breast Cancer Res Treat; 2019 Jul; 176(1):95-100. PubMed ID: 30977026
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
Roberts MC; Miller DP; Shak S; Petkov VI
Breast Cancer Res Treat; 2017 Jun; 163(2):303-310. PubMed ID: 28243896
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Significance of the Oncotype DX Recurrence Score in T
Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30.
Park S; Han Y; Liu Y; Toriola AT; Peterson LL; Colditz GA; Kim SI; Cho YU; Park BW; Park Y
Breast Cancer Res; 2019 Oct; 21(1):110. PubMed ID: 31619259
[TBL] [Abstract][Full Text] [Related]
15. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.
Dinan MA; Mi X; Reed SD; Hirsch BR; Lyman GH; Curtis LH
JAMA Oncol; 2015 May; 1(2):158-66. PubMed ID: 26181015
[TBL] [Abstract][Full Text] [Related]
16. Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer.
Han Y; Miao ZF; Lian M; Peterson LL; Colditz GA; Liu Y
Breast Cancer Res Treat; 2020 Dec; 184(3):915-925. PubMed ID: 32929567
[TBL] [Abstract][Full Text] [Related]
17. Tumor grade and progesterone receptor status predict 21-gene recurrence score in early stage invasive breast carcinoma.
Huang JL; Kizy S; Marmor S; Altman A; Blaes A; Beckwith H; Tuttle TM; Hui JYC
Breast Cancer Res Treat; 2018 Dec; 172(3):671-677. PubMed ID: 30196425
[TBL] [Abstract][Full Text] [Related]
18. The 21-Gene Recurrence Score Assay and Prediction of Chemotherapy Benefit: A Propensity Score-Matched Analysis of the SEER Database.
Choi IS; Jung J; Kim BH; Oh S; Kim J; Park JH; Park JH; Hwang KT
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32650374
[TBL] [Abstract][Full Text] [Related]
19. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
[TBL] [Abstract][Full Text] [Related]
20. Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy.
Enewold L; Geiger AM; Zujewski J; Harlan LC
Breast Cancer Res Treat; 2015 May; 151(1):149-56. PubMed ID: 25859924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
